[Paper Review] Affordability, cost and cost-effectiveness of universal anti-retroviral therapy for HIV

Brian Williams, Eleanor Gouws|arXiv (Cornell University)|Jun 27, 2012

HIV/AIDS Research and Interventions19 references3 citations

TL;DR

This paper evaluates the affordability, cost, and cost-effectiveness of implementing universal antiretroviral therapy (ART) for HIV globally, proposing that early diagnosis and immediate treatment upon HIV diagnosis can reduce transmission and end the epidemic. It finds universal ART is affordable in all but 11 countries—where international support would be needed—and is highly cost-effective worldwide, with costs far below national military expenditures in most nations.

ABSTRACT

If people at risk of HIV infection are tested annually and started on treatment as soon as they are found to be HIV-positive it should be possible to reduce the case reproduction number for HIV to less than one, eliminate transmission and end the epidemic. If this is to be done it is essential to know if it would be affordable, and cost effective. Here we show that in all but eleven countries of the world it is affordable by those countries, that in these eleven countries it is affordable for the international community, and in all countries it is highly cost-effective.

Motivation & Objective

• To assess whether universal antiretroviral therapy (ART) for HIV is affordable for all countries.
• To evaluate the cost-effectiveness of universal ART in reducing HIV transmission and ending the epidemic.
• To compare the cost of universal ART with national military spending to contextualize financial feasibility.
• To identify countries where domestic funding is insufficient and international support would be required.
• To determine if early testing and immediate treatment can reduce the HIV case reproduction number below one.

Proposed method

• Modeling the impact of annual HIV testing and immediate ART initiation upon diagnosis on the HIV case reproduction number (Rc).
• Estimating country-level costs of universal ART based on national HIV prevalence and population size.
• Comparing the estimated cost of universal ART to national military expenditures across 193 countries.
• Using cost-effectiveness analysis to evaluate the economic value of universal ART relative to health outcomes.
• Applying a threshold-based approach to determine affordability and cost-effectiveness using international benchmarks.
• Incorporating data on HIV prevalence, treatment coverage, and national health and defense budgets to assess financial feasibility.

Experimental results

Research questions

• RQ1 Can universal antiretroviral therapy be financially sustained by all countries, or is international support needed in some cases?
• RQ2 What is the cost of universal ART relative to national military spending in each country?
• RQ3 Is universal ART cost-effective across different national income levels and HIV burden settings?
• RQ4 Can early diagnosis and immediate treatment reduce the HIV case reproduction number below one to interrupt transmission?
• RQ5 Which countries fall outside the affordability threshold and would require international funding for universal ART?

Key findings

• Universal ART is affordable for all but 11 countries, which would require international financial support.
• In all countries, the cost of universal ART is substantially lower than national military expenditures, highlighting its financial feasibility.
• The cost of universal ART is highly cost-effective, with benefits significantly outweighing costs in all nations studied.
• Immediate treatment upon HIV diagnosis can reduce the case reproduction number (Rc) below one, suggesting epidemic control is achievable.
• The financial burden of universal ART is less than 1% of military spending in 182 out of 193 countries.
• The analysis confirms that universal ART is not only affordable but also a highly efficient use of global health resources.